Protocol Ledger

NCT04848753 · Phase III · ACTIVE NOT RECRUITING

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Interventional Phase III clinical trial protocol NCT04848753 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-12 Enrollment: 663 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04848753
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)663 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04848753
Protocol FieldVerified Registry Value
NCT IdentifierNCT04848753
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment663 participants (ACTUAL)
Registered Start Date2021-05-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04848753
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
The Second Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->
The Fourth Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI